Abbott's (ABT) phase 2b study results, "Aviator," showed high sustained viral response rates at 12 weeks post-treatment in all 8- and 12-week arms, with combinations of direct acting antivirals or DAAs given with and without ribavirin or RBV. Results would be presented at the President's Press Conference and the latebreaking clinical trials session at the Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease in Boston.
Based on promising results from Aviator, Abbott has selected triple-DAA regimens, with and without ribavirin, to move forward into phase 3 trials. Further, results from the 12-week triple-DAA regimen without RBV in treatment naïve patients showed: SVR12 was achieved in 87.3 percent of GT1 patients, SVR12 in GT1a patients was 83 percent, SVR12 in GT1b patients was 96 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.